Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 590-598

  Wagner, Carrie ^a   Chen, Dion ^a   Fan, Hongtao ^a,b   Hsia, Elizabeth C ^a   Mack, Michael ^a   Emery, Paul ^c   Fleischmann, Roy M ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Biomarkers; Golimumab; Methotrexate; Radiographic progression; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA FETOPROTEIN; AMYLOID P COMPONENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 125 ANTIGEN; CD40 LIGAND; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DEOXYPYRIDINOLINE; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; GOLIMUMAB; GOLIMUMAB PLUS METHOTREXATE; HAPTOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 16; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PLACEBO; PYRIDINOLINE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BONE RADIOGRAPHY; BONE TURNOVER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

BIOMARKERS; GOLIMUMAB; METHOTREXATE; RADIOGRAPHIC PROGRESSION; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CD40 LIGAND; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84876950286     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120889     Document Type: Article

References (22)

1. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93. (Pubitemid 38924385)
2. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74-8.
3. Bresnihan B. Rheumatoid arthritis: Principles of early treatment. J Rheumatol Suppl. 2002 Nov;66:9-12. (Pubitemid 35266005)
4. Keystone E. Recent concepts in the inhibition of radiographic progression with biologics. Curr Opin Rheumatol 2009;21:231-7.
5. Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
6. Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, et al. Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 2011;38:242-6.
7. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-47. (Pubitemid 47585418)
8. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6. (Pubitemid 36135386)
9. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808. (Pubitemid 351650500)
10. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2012 Jul 13 [E-pub ahead of print].
11. Simponi: Package insert. Horsham, PA: Janssen Biotech Inc.; 2011.
12. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
13. Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.
14. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
15. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
16. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
17. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
18. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. (Pubitemid 34620189)
19. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
20. Lee HY, Jeon HS, Song EK, Han MK, Park SI, Lee SI, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappa B-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006;54:1747-58.
21. Guise TA. Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009;23:2117-23.
22. Schneider MR, Sibilia M, Erben RG. The EGFR network in bone biology and pathology. Trends Endocrinol Metab 2009;20:517-24.